Track petrelintide in Peptimes™
Petrelintide (ZP8396) is an investigational drug: it is being studied in clinical trials, including Phase 3 trials sponsored by Hoffmann-La Roche. (Source: ClinicalTrials.gov.)
Is petrelintide FDA-approved?
No. Petrelintide is investigational: it's being studied in clinical trials and isn't FDA-approved for any use.
Petrelintide
Also: ZP8396, ZP-8396, RO7895515
- Status label in the Peptimes Library
- Phase 3 Trials
- Routes in Peptimes
- Subcutaneous
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-approved for any use. Drugs@FDA lists no application with petrelintide as an active ingredient.
Source: Drugs@FDA, checked 1 Nov 2026
Investigational
Yes.
Source: ClinicalTrials.gov, checked 1 Nov 2026
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In animals or the lab
Its developers at Zealand Pharma describe petrelintide as a long-acting analogue of human amylin, designed to stay chemically stable at about neutral pH while keeping its potency in lab and animal tests.
Source: PMID 41217931, checked 1 Nov 2026
How to track it in Peptimes
Add petrelintide in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 3 Trials”, which describes its investigational status. It isn’t an approval.
- Logging: the amount you took and how you feel.
- Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell petrelintide or any other compound.
More sources
- NIH, ClinicalTrials.gov, NCT07843498, checked 1 Nov 2026: a Phase 3 study of petrelintide sponsored by Hoffmann-La Roche, recruiting, with the other names RO7895515 and ZP8396.
- NIH, ClinicalTrials.gov, studies of petrelintide, checked 1 Nov 2026: registered studies, including Phase 1, 2 and 3 studies.
- FDA, Drugs@FDA, checked 1 Nov 2026: no application lists petrelintide as an active ingredient.
- FDA, Global Substance Registration System, Petrelintide, checked 1 Nov 2026: a modified peptide, and the code name ZP-8396.